Dear Ms. Tindle:

Please refer to your Supplemental New Drug Applications (sNDAs) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

<table>
<thead>
<tr>
<th>Application</th>
<th>Drug Product</th>
<th>Submitted on</th>
<th>Received on</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 020235/S-054</td>
<td>Neurontin (gabapentin) Capsules</td>
<td>03/30/2012</td>
<td>03/30/2012</td>
</tr>
<tr>
<td>NDA 020235/S-055</td>
<td>Neurontin (gabapentin) Capsules</td>
<td>07/30/2012</td>
<td>07/30/2012</td>
</tr>
<tr>
<td>NDA 020235/S-056</td>
<td>Neurontin (gabapentin) Capsules</td>
<td>12/19/2012</td>
<td>12/19/2012</td>
</tr>
<tr>
<td>NDA 020882/S-038</td>
<td>Neurontin (gabapentin) Tablets</td>
<td>03/30/2012</td>
<td></td>
</tr>
<tr>
<td>NDA 020882/S-039</td>
<td>Neurontin (gabapentin) Tablets</td>
<td>07/30/2012</td>
<td></td>
</tr>
<tr>
<td>NDA 020882/S-040</td>
<td>Neurontin (gabapentin) Tablets</td>
<td>12/19/2012</td>
<td></td>
</tr>
<tr>
<td>NDA 021129/S-035</td>
<td>Neurontin (gabapentin) Pediatric oral Suspension</td>
<td>03/30/2012</td>
<td></td>
</tr>
<tr>
<td>NDA 021129/S-036</td>
<td>Neurontin (gabapentin) Pediatric oral Suspension</td>
<td>07/30/2012</td>
<td></td>
</tr>
<tr>
<td>NDA 021129/S-037</td>
<td>Neurontin (gabapentin) Pediatric oral Suspension</td>
<td>12/19/2012</td>
<td></td>
</tr>
</tbody>
</table>

These “Changes Being Effected” supplements provide for:

- Addition of “elevated creatine kinase” to the ADVERSE REACTIONS – Postmarketing Experience section of labeling.
- Addition of “rhabdomyolysis” to the ADVERSE REACTIONS – Postmarketing Experience section of labeling.
- Addition of information to the DRUG ABUSE AND DEPENDENCE section of labeling.

Reference ID: 3301312
We have completed our review of these supplemental applications, as amended. These are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.


The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at [http://www.fda.gov/opacom/morechoices/fdaforms/cder.html](http://www.fda.gov/opacom/morechoices/fdaforms/cder.html).
instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Su-Lin Sun, PharmD, Regulatory Project Manager, at (301) 796-0036 or email su-lin.sun@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Eric Bastings, M.D.
Deputy Director
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC P BASTINGS
05/01/2013